The Lancet Oncology · 2011 · 917 citations · 23 references
MedicinePharmacologyPharmacotherapyHematologic OncologyMedical OncologyOncology PharmacotherapyCancer ImmunotherapyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyMultiple MyelomaBortezomib TherapyBortezomib-based TherapyMultiple Myeloma ChemotherapyMultiple Myeloma TherapyMultiple Myeloma TreatmentRefractory Multiple MyelomaRelapsed Multiple MyelomaSubcutaneous Medication Administration
23
International Staging System for Multiple Myeloma
Philip R. Greipp, Jesús F. San Miguel, Brian G.M. Durie et al. · Journal of Clinical Oncology · 2005 · 2.9K citations
Medicine, Hematology, Oncology +14
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text
International uniform response criteria for multiple myeloma
Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations
Medicine, Hematology, Oncology +12
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · New England Journal of Medicine · 2005 · 2.5K citations · Full text
Improved survival in multiple myeloma and the impact of novel therapies
Shaji Kumar, S. Vincent Rajkumar, Angela Dispenzieri et al. · Blood · 2007 · 2.3K citations · Full text
Medicine, Oncology, Pharmacotherapy +14